EGFR and non-small cell lung carcinoma: A recent phase III randomized study showed that the combination of gefitinib, an EGFR inhibitor, with carboplatin and pemetrexed, which are chemotherapeutic agents, resulted in an increased PFS in patients with NSCLC with EGFR mutations when compared to gefitinib alone, with an increase from 11.2 months to 20.9 months.